Successful trial results highlight the strong potential for POLB 001 as the asset was shown to have a potent effect on blocking the systemic and localised LPS-induced inflammatory response in a dose dependent manner. Subjects treated with POLB 001 exhibited a marked reduction in multiple markers of systemic and localised inflammation compared with placebo. This data demonstrates the expected utility of POLB 001 in severe influenza and other inflammatory conditions. We increase our probability of ....